Skip to main content
Sign In

Search

Search for a Specific Type of Clinical Trial
Note: This page will take a moment to download because of the quantity of trials.

Feedback

Did you have problems using this page? Please fill out our Feedback Form

Clinical Trials

Volunteer to Be Part of a Research Study

Page through all School of Medicine clinical and research trials below. There are two categories:

  • Detailed Trial Descriptions, submitted by researchers, includes trial specifics and contact information.

  • Additional Clinical Trials, which include basic study details. To contact the researcher either Google the PI (primary investigator) name or use our campus directory.

If you are a researcher seeking volunteers and your study is not posted, please
submit your Web ad here.
  

Detailed Trial Descriptions

 Results From Research and Clinical Trials : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 5, items 1 to 30 of 126.
TitleStudy GoalsEligibility CriteriaContact Information
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 5, items 1 to 30 of 126.
Are you stopping your birth control because you want to become pregnant? 13-1594
To look at contraception rates after birth control discontinuation.
Women 18-35 who are planning to, or have recently stopped their birth control because they want to become pregnant.
PI: Teal, Stephanie
  • 303-724-2013
  • Sandra.cano@ucdenver.edu
Type 1 Diabetes Research Study 11-0649
To study the effects of a medication on metabolism and blood vessel function.
Persons 25-50 years old with or without type 1 diabetes with normal blood pressure and exercise vigorously no greater than 3 times per week.
PI: Schauer, Irene
  • 720-848-6690
  • Ellen.Lyon@ucdenver.edy
JUST DIAGNOSED WITH SHINGLES? 13-2122
This study will look at the body's immune response (how the body fights infection) to the onset of shingles. 1-2 study visits for blood draws, over the course of 3 months.
18+ years of age; NO PRIOR HISTORY of shingles; have NEVER received the shingles vaccine; have DEVELOPED SHINGLES within the last 10 days.
PI: Levin, Myron
  • 303/724-2454
  • nancy.lang@ucdenver.edu
protein and infant growth: Do you have a child younger than 6 months 14-0139
Participants in this research study on protein from complementary foods (meat or dairy) and infant growth, will learn how protein consumption affects your child’s growth, fat gain, and gut health from 6 to 12 months of age.  
To qualify, you child needs to be: 1. Formula fed, or not on breast-milk longer than 1 month. 2. Younger than 6 months. 3. Generally healthy. You will receive commercially available complementary foods for 7 months, Receive infant formula at no cost for 7 months, You will know your child's body fat and fat free mass and blood lipid level.
PI: Krebs, Nancy
  • 303-724-3248
  • minghua.tang@ucdenver.edu
Volunteers Needed: Thinking and Memory in Parkinson's Disease 13-2724
This research study aims to better understand how changes in brain activity may be related to thinking problems in Parkinson's Disease and to determine whether, by stimulating certain areas, thinking and memory can be improved.
Person's with Parkinson's Disease with mild thinking and memory problems. Between 40-90 years old. No metal in your body. No implant. Not taking any medication to improve memory. Not taking stimulants or seizure medication.
PI: Kluger, Benzi
  • 303-724-5973
  • mailto:isabelle.buard@ucdenver.edu
Research Participants Needed 14-0770
We are looking for participants with diabetes to serve as a standard for comparison when describing physical function outcomes before and during prosthetic rehabilitation.
Inclusion Criteria: 1) 50-85 years of age. 2) Able to walk continuously without assistance (i.e., do not use a cane or walker) for 10 minutes and physically active (e.g., participate in recreational activities like walking, jogging, hiking). 3) Diagnosis of diabetes. 4) No other neurological, vascular or cardiac problems that limit function. 5) Body mass index
PI: Christiansen, Cory
  • 303-724-9590
  • krista.m.sanchez@ucdenver.edu
HAVE YOU OR YOUR CHILD BEEN DIAGNOSED WITH ASTHMA? HS-2827
We are looking for volunteers to participate in an N.I.H. funded research study.
Children 12 years of age and older and non-smoking Adults who have mild to moderate asthma who are not currently taking inhaled steroid medication
PI: Martin, Richard
  • 303-398-1443
  • martinlab@njhealth.org
Do You or Someone You Know Suffer From Relapse Remitting Multiple Sclerosis (RRMS)? 13-2209
The University of Colorado Denver is conducting a clinical trial to evaluate the effectiveness, safety and tolerability of two doses of oral administration of laquinimod in subjects with Relapse Remitting Multiple Sclerosis (RRMS). Patients that suffer from RRMS may experience a gradual increase of their disability over time. The purpose of this study is to find out whether laquinimod is safe and effective in slowing the rate of disability progression.
-Between the ages of 18 and 55 -Have clinically confirmed diagnosis of Multiple Sclerosis (MS) with relapse onset disease or relapsing-remitting disease course -Have had at least one documented relapse within 12 months prior to starting this study -Have not been treated with Natalizumab (Tysabri) or Rituximab 2 years prior to starting this study
PI: Vollmer, Timothy
  • 303-724-6351
  • Nicola.Haakonsen@ucdenver.edu
Sedentary Behavior Research Study 14-0429
This research study plans to learn more about how the time we spend seated affects your health
Healthy male and female Age: 19-45 With BMI: 27-33 you may check this at: http://nhlbisupport.com/bmi/ Be seated more than 6hr/d Be physically active on less than 3-4 days/wk
PI: Bergouignan, Audrey
  • 303-724-9026
  • nathan.dejong@ucdenver.edu
Healthy Minority Volunteers Needed 13-0427
This study plans to learn more about how tenofovir and emtricitabine (Truvada) build up in cells in blood and hair. Participation will include two 12 week dosing periods separated by a 12 week washout period (total duration is 36 weeks). Eligible participants will be given the supply of medications for the study.
Documented negative testing for HIV and hepatitis B Not at risk for HIV Study population balanced by Caucasian, African-American, Hispanic race. African American and Hispanic participants are currently needed. Age 18-50 years Able to meet study personnel on Anschutz Medical Campus for directly observed dosing with study medication, or by audio-visual communication with a mobile cellular device when off Campus
PI: Anderson, Peter
  • 303-724-8296
  • ariel.hodara@ucdenver.edu
University of Colorado Recruiting Patients for a Clinical Research Study for Psoriasis 13-2720
The research study compares the effect of treatments, such as Humira and phototherapy, on inflammation in the body and cardiovascular disease. This study will look for systemic vascular inflammation in subjects enrolled in this study, with a test called FDG-PET/CT (Fluorodeoxyglucose-positron emission tomography computed tomography).
We are looking for males and females 18 years of age and older with a diagnosis of psoriasis for at least 6 months
PI: Armstrong, April
  • 720-848-3607
  • aleksandra.florek@ucdenver.edu
Volunteers Needed for Research Study 13-2035
The purpose of the study is to evaluate the effect of mental concentration on nerve and muscle excitability.
We are looking for healthy men and women aged 21-50 years who do not have neck or shoulder pain to participate in a research study.
PI: Maluf, Katrina
  • 3037240066
  • ANP.Lab@ucdenver.edu
Diabetic Male and Female Volunteers Needed for Exercise Research Study 06-0062
Evaluate exercise function during single leg calf exercise in people with or without type 2 diabetes
Healthy Adults 30-70 with Type 2 diabetes but not using insulin.  Must be a non-smoker who exercise no more than one time per week and have a BMI of 25-40
PI: Regensteiner, Judith
  • 303-724-2255
  • shawna.mcmillin@ucdenver.edu
Trouble Controlling your Type 2 Diabetes? 12-1529
Investigational non-surgical device that may help decrease blood sugar.
Adults 21-65 with type 2 Diabetes and not on oral medication, not taking insulin. Must have an A1C level of 8-10%, be overweight or obese and willing to attend study visits
PI: Wyatt, Holly
  • GI Dynamics
  • Jeanneanne.breen@ucdenver.edu
Project Safe - THE IMPACT OF MEDICAL MARIJUANA IN METROPOLITAN DENVER 11-0718
To learn more about the medical marijuana industry in Colorado and its relationship to health risk behaviors and healthcare.
Persons 18+ currently a medical marijuana patient or currently using non-medical marijuana
PI: Booth, Robert
  • 1-800-429-9240
  • Eric.Kovalsky@ucdenver.edu
Persons with active, moderate to severe ulcerative colitis needed 12-1408
This study is being conducted to investigate the efficacy of methotrexate in treating ulcerative colitis in patients that have active, moderate to severe colitis and have failed other types of therapies.
Inclusion: Ages 18-70 Ulcerative colitis has been diagnoses by routine criteria At least one of the following applies: steroid dependent failed 5-ASA (mesalamine) therapy, such as Asacol Failed/lost response to infliximab (Remicade) Intolerant/unresponsive to azathioprine (Imuran) or 6-MP (purinethol) therapy Exclusion (partial): Existing pregnancy, lactation, or planned pregnancy (men and women)
PI: Gerich, Mark
  • 303-724-7875
  • katelyn.cowan@ucdenver.edu
3D Gait Analysis Participants Needed 13-1857
Research study investigating the coordination of walking
Subject with Spastic Cerebral Palsy Inclusion Criteria: ● Males and females between the ages of 7 and 100 years of age. ● Retrospective gait data must contain a complete lower body marker set and valid kinetic data. ● Only gait data trials of the subject walking unassisted will be used. ● Diagnosis of spastic cerebral palsy. ● Exhibits either stiff knee gait pattern, characterized by insufficient and delayed peak knee flexion during swing (less than 45), or crouch gait pattern, characterized by excessive hip flexion and knee flexion (greater than 30 throughout stance). Cerebellar Ataxic Gait Subject Inclusion Criteria: ● Males and females between the ages of 7 and 100 years of age. ● Ability to walk continuously and unassisted for 3 minutes. ● If under the age of 18, parent consent and subject assent. ● Diagnosis of either Friedreich's or spinocerebellar ataxia. Subject with Lower Limb Amputation Inclusion Criteria: ● Males and females between the ages of 7 and 100 years of age. ● Ability to walk continuously and unassisted for 3 minutes. ● If under the age of 18, parent consent and subject assent. ● Has been using the prosthetic limb for at least 6 months for independent ambulation prior to gait analysis at CGMA. ● Below knee or above knee amputation.
PI: Worster, Kate
  • 720-777-8216
  • worsterk@gmail.com
Would you like to participate in a study to improve the understanding of how emotions and symptom distress affect adherence to hormonal therapy in breast cancer? 13-0371
The purpose of this study is to understand how emotional factors and symptom distress affect adherence to hormonal therapy in women that have completed all other treatment for breast cancer.   
Women Breast Cancer Survivor Age 21-70 years old Within 24 months of starting hormonal therapy: Aromatase Inhibitors or Tamoxifen (Aromatase Inhibitors, Exemestane (aromasin), Letrolzole (Femara), Anastrozole (Arimidex).
PI: Grossman, Vicki
  • 720-352-3316
  • Vicki.Grossman@ucdenver.edu
Do you spend most of your day sitting? WIRB #20131967
The Anschutz Health & Wellness Center is seeking participants for a new research project to determine if exercise performed throughout the day is more energizing compared to exercise performed in the morning or if you do not exercise.
Participants must meet the following criteria: - Sedentary - Between the ages of 25 - 50 - BMI between 18.5 and 29.9 kg/m^2 - Non-smoker
PI: Hill, James
  • 303-724-8299
  • Eats.Study@ucdenver.edu
Pharmacokinetics Research Study of Nontuberculous Mycobacteria Antibiotics in HEALTHY people and in people with CYSTIC FIBROSIS 14-1043
We are conducting a research study to test if levels of antibiotics used to treat nontuberculous mycobacteria infections are different between people with and without cystic fibrosis. The goal of our study is to provide recommendations for treatment of CF patients with lung disease due to nontuberculous mycobacterial infection.
Teenagers and adults who are either healthy or who have cystic fibrosis and are 16 to 45 years old may be eligible to participate in this study.
PI: Martiniano, Stacey
  • 720-777-2945
  • Meg.Anthony@childrenscolorado.org
Have the Flu? Living with a chronic medical condition, too? 11-0101
Influenza (the flu) can be life-threatening. Approximately 24,000 people in the United States die each year of this disease. We are conducting a study to determine whether treating patients with a combination of several drugs instead of just one helps them to get better faster.
You qualify for our study if you: •Have been diagnosed with the flu •Are at least 18 years of age •Have an existing medical condition that puts you at increased risk for complications from the flu—conditions such as diabetes; heart, lung, and kidney disease; COPD; and asthma
PI: Barron, Michelle
  • 303-724-0712
  • Graham.Ray@ucdenver.edu
Healthy Postmenopausal Women Needed for Cardiovascular Research Study 14-0532
The purpose of this study is to investigate how the health and function of arteries respond to estrogen, resveratrol, and exercise.
Postmenopausal women between the ages of 50-70 years, nonsmokers, not currently taking hormone replacement therapy or exercising vigorously more than 2 days per week.
PI: Moreau, Kerrie
  • 303-724-7465
  • cemal.ozemek@ucdenver.edu
Would your child like to participate in groundbreaking research and earn money? 12-1587
We are looking for healthy controls to participate in a research study investigating the cause of idiopathic scoliosis in adolescents.
Girls, 11-12 years old, do not have scoliosis or any other skeletal disorders, a BMI under 20 kg/m2, have not yet started their period, and have no family history of scoliosis
PI: Hadley Miller , Nancy
  • 720-777-4626
  • robin.baschal@childrenscolorado.org
Do you or someone you know have a food allergy to soy? 14-0097
We are studying the accuracy of a food allergy blood test.  
-Are age 1 to 21 and -Do have an IgE level greater than 0.35 to wheat OR soy or -Have had a positive skin test to wheat OR soy or -Have a clinically diagnosed wheat OR soy allergy -Do NOT use >500 micrograms/day fluticasone or equivalent -Do NOT have severe asthma, daily oral steroid dosing, or asthma requiring hospitalization within a year or an ER visit in the past 6 months -Do NOT have active EoE (or recently diagnosed) -Have NOT used biologic or allergen immunotherapy within the past year
PI: Fleischer, David
  • 720-777-2569
  • Hannah.Gilbert@childrenscolorado.org
Participants Needed For Research on Military Veterans And Service Dogs 14-2041
The purpose of this study is to explore the relationship between military veterans and their service dogs. Veterans will participate in one on one interviews.
Are you a military veteran? Do you have a service dog? Are you 18-89 years old? If you answered yes to the above, contact C-P.A.W.W. today.
PI: Krause-Parello, Cheryl
  • (303)-724-8282
  • CPAWW@ucdenver.edu
Apoyo con Cariño: Improving Palliative Care for Latinos with Cancer 12-0592
We want to understand if a patient navigator can help Latino patients and their family caregivers deal with cancer. Our project hopes to improve palliative or comfort care to patients with advanced cancer. The goal is to prevent or relieve suffering for people facing serious illness. Research is needed to find out if a patient navigator can help patients and family caregivers.
Adults (18 years and older) who self-identify as Latino and have Stage III-IV cancer.
PI: Fischer MD, Stacy
  • 303-724-7410
  • danielle.kline@ucdenver.edu
Seeking Adults with NO History of Eczema, Allergies or Asthma HS-2581
The purpose of this study is to determine why some individuals with atopic dermatitis are at increased risk for skin infections.
Males and females between 18 and 64years of age with no history of Allergies, Eczema, or Asthma
PI: Leung, Donald
  • 303-270-2222
  • lairsmithj@njhealth.org
SPIROMICS-Subpopulations and Intermediate Outcome Measures in COPD Study HS-2678
To identify subpopulations of COPD patients in order to develop newer and more effective treatments and to clearly define measureable end points so that treatment effects may be accurately assessed in a shorter period of time.
Be willing to undergo study procedures Be between the age of 40 and 80 years old Have smoked fewer than one pack of cigarettes per day for one year OR have smoked more than one pack of cigarettes per day for 20 years
PI: Bowler, Russell
  • 303-270-2827
  • HerrudT@njHealth.org
Psychiatric Medication Study 11-0965
We are looking for volunteers to participate in a research study investigating how psychiatric medications are processed in people who are diagnosed with HIV-1 compared to subjects who are on psychiatric medications who are HIV-negative. You can participate in this study if you are HIV negative and taking certain psychiatric medications.
To Qualify: Must between the ages of  2 to <25 years; Be HIV-Negative; On a steady dose of Psychiatric Medication (Celexa, Lexapro, Risperdal, Zoloft, Prozac, Paxil or generic equivalents)
PI: McFarland, Elizabeth
  • 720-777-6257
  • jenna.wallace@childrenscolorado.org
HEALTHY MEN AND WOMEN 60-85 YEARS OLD Wanted to participate in a research study 13-2594
To test whether interrupting prolonged sitting with short bouts of moderate intensity walking can improve health
We are looking for men and women who:  Are age 60-85 years old  Healthy – no diagnosed disease  Not on glucose lowering medication  Do not participate in regular exercise  Ambulatory – able to walk without assistance  Are non-smokers
PI: Lyden, Kate
  • Kate Lyden
  • kate.lyden@ucdenver.edu

​Additional Clinical Trails

 Results From Research : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 18, items 1 to 30 of 530.
Protocol TitlePI NameInstitution Number
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 18, items 1 to 30 of 530.
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy” – Sponsor SOTIO Sponsor Protocol No. SP005 WIRB Protocol No. 20141765
Flaig, Thomas13-2709
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Solid Tumors, Including Glioma, with an IDH1 Mutation Sponsor Protocol No. AG120-C-002 WIRB Protocol No. 20140544
Gore, Lia14-0012
A safety study for MSB0010445 in combination with Stereotactic Body Radiation in advanced melanoma subjects following prior treatment with ipilimumab Sponsor Protocol No. EMR 062235-005 WIRB Protocol No. 20140683
Lewis, Karl14-0050
A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd- Sulfate) in Combination with Docetaxel, Compared with Placebo in Combination with Docetaxel, in Patients receiving second line treatment for Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB – IV)(SELECT-2) Sponsor Protocol No. D1532C0064 WIRB Protocol No. 20121812
Oton, Ana14-0084
Evaluation of Potential Allergenicity of New Soybean Varieties Sponsor Protocol No. Monsanto Soy Allergen WIRB Protocol No.20131161
Fleischer, David14-0097
A single arm, open-label, phase II study to assess the efficacy of the dual VEGFR-FGFR tyrosine kinase inhibitor, lucitanib, given orally as a single agent to patients with FGFR1-driven lung cancer. Sponsor Protocol No. E-3810-II-02. WIRB Protocol No. 20140760
Camidge, David14-0100
A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244, Hyd-Sulfate) in Combination with Dacarbazine Compared with Placebo in Combination with Dacarbazine as First Systemic Therapy in Patients with Metastatic Uveal Melanoma (SUMIT) Sponsor Protocol No. D1344C00001 WIRB Protocol No.20141762
Lewis, Karl14-0108
An Open-Label, Randomized, Phase 3 Trial of Nivolumab versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer Sponsor Protocol No. CA209026 WIRB Protocol No. 20140357
Camidge, David14-0243
A MULTICENTER PHASE 1A/1B ASCENDING DOSE STUDY OF DCC-2701 TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS IN PATIENTS WITH ADVANCED SOLID TUMORS Sponsor Protocol No. DCC-2701-01-001 WIRB Protocol No. 20142004
Leong, Stephen14-0244
A Phase 2, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Subjects with HER2+ AR+ Metastatic or Locally Advanced Breast Cancer Sponsor Protocol No.9785-CL-1121 WIRB Protocol No.20140662
Elias, Anthony14-0330
MPACT Extension Study: Multicenter, Survival Data Collection in Subjects Previously Enrolled in Protocol CA046 Sponsor Protocol No. ABI-007-PANC-CA046 WIRB Protocol No. 20140499
Weekes, Colin14-0354
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer Sponsor Protocol No. INCB 18424-268 WIRB Protocol No. 20141874
Elias, Anthony14-0356
A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination with Topotecan (Hycamtin®) in Patients with Solid Tumors. Sponsor Protocol No. ME-344-002, WIRB Protocol No. 20140982
Diamond, Jennifer14-0413
A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial to Evaluate the Duration of Action of Baclofen ER Capsules (GRS) in Subjects with Spasticity due to Multiple Sclerosis (MS) Sponsor Protocol No.CLR_11_03 WIRB Protocol No. 20141173
Corboy, John14-0474
A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF MPDL3280A IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER Sponsor Protocol No. GO29293 WIRB Protocol No. 20140697
Flaig, Thomas14-0481
A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-X) Sponsor Protocol No. H9B-MC-BCDX WIRB Protocol No. 20121280
Striebich, Christopher14-0482
DuraSeal Exact Spine Sealant System Post Approval Study Sponsor Protocol No. COV-DRSS-0002 WIRB Protocol No. 20111669
Patel, Vikas14-0509
A Randomized Phase 3 Open Label Study of Nivolumab versus Bevacizumab and a Safety Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Adult Subjects with Recurrent Glioblastoma (GBM)(CheckMate 143: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 143). Sponsor Protocol No. CA209143. WIRB Protocol No. 20140894
Damek, Denise14-0518
A Phase I, Dose-escalation Study of the Safety, Pharmacokinetics and Efficacy of Weekly Intravenous Briciclib in Patients with Advanced Solid Tumors Sponsor Protocol No. 08-02 WIRB Protocol No. 20141094
Jimeno, Antonio14-0565
A PHASE 1, DOSE ESCALATION STUDY OF PF-06664178 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS Sponsor Protocol No. B7401001 WIRB Protocol No. 20141074
Messersmith, Wells14-0581
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies Sponsor Protocol No. D3610C00001 WIRB Protocol No. 20141546
Kabos, Peter14-0583
A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction with Midazolam, and Safety and Tolerability in Patients with Advanced Malignancies Sponsor Protocol No. OPZ009 WIRB Protocol No. 20141700
Gore, Lia14-0589
A multicenter, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of SA237 as monotherapy in patients with neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD) Sponsor Protocol No. SA-309JG WIRB Protocol No. 20141301
Bennett, Jeffrey14-0598
Evaluation of the Effectiveness of Evolution® Biliary Stent System – Fully Covered. Sponsor Protocol No. 10-014. WIRB Protocol No. 20142167
Shah, Raj14-0602
RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT-NAÏVE ANAPLASTIC LYMPHOMA KINASE−POSITIVE ADVANCED NON−SMALL CELL LUNG CANCER Sponsor Protocol No. BO28984 WIRB Protocol No. 20140921
Camidge, David14-0643
A prospective, global, multicenter, treatment registry study of intravenous immunoglobulin maintenance therapy in alloantibody positive renal allograft recipients Sponsor Protocol No.2014.3.24_Version 1 DSA Study WIRB Protocol No. 20141210
Cooper, James14-0648
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF LEBRIKIZUMAB IN ADOLESCENT PATIENTS WITH UNCONTROLLED ASTHMA WHO ARE ON INHALED CORTICOSTEROIDS AND A SECOND CONTROLLER MEDICATION Sponsor Protocol No. WB28183 WIRB Protocol No. 20131735
Szefler, Stanley14-0698
A Phase 2 open-label study in patients with recurrent Genotype 1 hepAtitis C post-orthotopic Liver transplAnt to eXplore the safety and efficacY of simeprevir and sofosbuvir with and without ribavirin Sponsor Protocol No.TMC435HPC2009 WIRB Protocol No.: 20141146
Burton, James14-0746
A randomized, parallel-group, double-blind, placebo-controlled, multi-center study of Eculizumab for the prevention of delayed graft function after kidney transplantation in adult subjects at increased risk of delayed graft function. Sponsor Protocol No.ECU-DGF-201 WIRB Protocol No.20141172
Wiseman, Alexander14-0748
Phase 1/2 Study of PF-03084014 in Combination with Gemcitabine and nab-Paclitaxel in Patients with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Sponsor Protocol No. A8641019 WIRB Protocol No. 20140800
Messersmith, Wells14-0762


Contact Us

Building 500 - 13001 E. 17th Place, Campus Box C290, Aurora, CO 80045

Learn more